A5021777037- SARS-CoV-2 and COVID-19 Research
- Mosquito-borne diseases and control
- Viral Infections and Vectors
- Viral Infections and Outbreaks Research
- Viral gastroenteritis research and epidemiology
- Immunotherapy and Immune Responses
- SARS-CoV-2 detection and testing
- RNA Interference and Gene Delivery
- Influenza Virus Research Studies
- Vector-Borne Animal Diseases
- Animal Virus Infections Studies
- vaccines and immunoinformatics approaches
- COVID-19 Clinical Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Insect symbiosis and bacterial influences
- Viral Infections and Immunology Research
- Immune Cell Function and Interaction
- Malaria Research and Control
- Tuberculosis Research and Epidemiology
- Cancer Research and Treatments
- T-cell and B-cell Immunology
- COVID-19 Impact on Reproduction
- interferon and immune responses
- Virology and Viral Diseases
- Toxin Mechanisms and Immunotoxins
University of Washington
2020-2024
LabCorp (United States)
2024
Health Decision Technologies (United States)
2024
TRIA Bioscience (United States)
2022-2023
Wake Forest University
2022
The University of Texas Medical Branch at Galveston
2014-2021
Infectious Disease Research Institute
2017-2020
Io Therapeutics (United States)
2020
Institute of Infection and Immunity
2016
John Sealy Hospital
2016
The coronavirus disease 2019 (COVID-19) pandemic, caused by infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is having a deleterious impact on health services and global economy, highlighting urgent need for an effective vaccine. Such vaccine would to rapidly confer protection after one or two doses be manufactured using components suitable scale up. Here, we developed
Mycobacterium tuberculosis (M.tb), a bacterial pathogen that causes disease (TB), exerts an extensive burden on global health. The complex nature of M.tb, coupled with different TB stages, has made identifying immune correlates protection challenging and subsequently slowing vaccine candidate progress. In this work, we leveraged two delivery platforms as prophylactic vaccines to assess immunity subsequent efficacy against low-dose ultra-low-dose aerosol challenges M.tb H37Rv in C57BL/6 mice....
Abstract The ongoing circulation of influenza A H5N1 in the United States has raised concerns a pandemic caused by highly pathogenic avian influenza. Although stockpiled and is prepared to produce millions vaccine doses address an pandemic, currently circulating viruses contain multiple mutations within immunodominant head domain hemagglutinin (HA) compared antigens used vaccines. It unclear if these vaccines will need be updated match contemporary strains. Here we show that replicating RNA...
Since the first demonstration of in vivo gene expression from an injected RNA molecule almost two decades ago,1Wolff J.A. Malone R.W. Williams P. Chong W. Acsadi G. Jani A. Felgner P.L. Direct transfer into mouse muscle vivo.Science. 1990; 247: 1465-1468Crossref PubMed Scopus (3242) Google Scholar field RNA-based therapeutics is now taking significant strides, with many cancer and infectious disease targets entering clinical trials.2Kaczmarek J.C. Kowalski P.S. Anderson D.G. Advances...
ABSTRACT Chikungunya virus (CHIKV) is a reemerging arbovirus capable of causing explosive outbreaks febrile illness, polyarthritis, and polyarthralgia, inflicting severe morbidity on affected populations. CHIKV can be genetically classified into 3 major lineages: West African (WA); East, Central, South (ECSA); Indian Ocean (IOL); Asian. Additionally, the (IOL) sublineage emerged within ECSA clade Asian/American Asian clade. While differences in epidemiological pathological characteristics...
Monoclonal antibody (mAb) therapeutics are an effective modality for the treatment of infectious, autoimmune, and cancer-related diseases. However, discovery, development, manufacturing processes complex, resource-consuming activities that preclude rapid deployment mAbs in outbreaks emerging infectious Given recent advances nucleic acid delivery technology, it is now possible to deliver exogenous mRNA encoding situ expression following intravenous (i.v.) infusion lipid...
BackgroundCrimean-Congo hemorrhagic fever virus is the cause of a severe with cases reported throughout wide-geographic region. Spread by bite infected ticks, contact livestock or in health care setting, disease begins as non-specific febrile illness that can rapidly progress to manifestations. Currently, there are no approved vaccines and antivirals such ribavirin have unclear efficacy. Thus treatment mostly limited supportive care.MethodsIn this report we evaluated an alphavirus-based...
RNA vaccines possess significant clinical promise in counteracting human diseases caused by infectious or cancerous threats. Self-amplifying replicon (repRNA) has been thought to offer the potential for enhanced potency and dose sparing. However, repRNA is a potent trigger of innate immune responses vivo, which can cause reduced transgene expression dose-limiting reactogenicity, as highlighted recent trials. Here, we report that multivalent vaccination, necessitating higher doses total RNA,...
Abstract Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne febrile illness with wide geographic distribution. In recent years the range of virus (CCHFV) and its tick vector have increased, placing an increasing number people at risk CCHFV infection. Currently, there are no widely available vaccines, although World Health Organization recommends ribavirin for treatment, efficacy unclear. Here we evaluate promising replicating RNA vaccine in rhesus macaque ( Macaca mulatta) model CCHF....
Malaria, caused by Plasmodium parasites, remains one of the most devastating infectious diseases worldwide, despite control efforts to lower morbidity and mortality. Both advanced candidate vaccines, RTS,S R21, are subunit (SU) vaccines that target a single falciparum (Pf) pre-erythrocytic (PE) sporozoite (spz) surface protein known as circumsporozoite (CS). These induce humoral immunity but fail elicit CD8 + T-cell responses sufficient for long-term protection. In contrast, whole-organism...
Despite mass public health efforts, the SARS-CoV2 pandemic continues as of late 2021 with resurgent case numbers in many parts world. The emergence variants concern (VoCs) and evidence that existing vaccines were designed to protect from original strains SARS-CoV-2 may have reduced potency for protection infection against these VoC is driving continued development second-generation can multiple VoC. In this report, we evaluated an alphavirus-based replicating RNA vaccine expressing Spike...
The recent emergence and rapid response to severe acute respiratory syndrome coronavirus 2 was enabled by prototype pathogen vaccine platform approaches, driven the preemptive application of RNA technology related Middle East coronavirus. Recently, National Institutes Allergy Infectious Diseases identified nine virus families concern, eight enveloped one nonenveloped family, for which generation is a priority. Although vaccines have been described variety viruses, roadmap their use against...
Immunization with mosaic-8b (nanoparticles presenting 8 SARS-like betacoronavirus [sarbecovirus] receptor-binding domains [RBDs]) elicits more broadly cross-reactive antibodies than homotypic SARS-CoV-2 RBD-only nanoparticles and protects against sarbecoviruses. To investigate original antigenic sin (OAS) effects on efficacy, we evaluated the of prior COVID-19 vaccinations in non-human primates mice anti-sarbecovirus responses elicited by mosaic-8b, admix-8b (8 homotypics), or immunizations,...
Chikungunya virus (CHIKV) is an arthritogenic alphavirus that during the last decade has significantly expanded its geographical range and caused large outbreaks of human disease around world. Although mortality rates associated with CHIKV are low, acute chronic illnesses by represent a significant burden largely affecting low middle income countries. This report summarizes current status vaccine development for CHIKV.
In December of 2013, chikungunya virus (CHIKV), an alphavirus in the family Togaviridae, was introduced to island Saint Martin Caribbean, resulting first autochthonous cases reported Americas. As January 2015, local and imported CHIKV has been 50 American countries with over 1.1 million suspected cases. causes a severe arthralgic disease for which there are no approved vaccines or therapeutics. Furthermore, lack commercially available, sensitive, affordable diagnostic assay limits...
The rapid generation of strong T cell responses is also highly desirable and viral vectors can have potent CD8+ cell-inducing activity. Immunity to leishmaniasis requires selective responses, with immunization schemes that raise either CD4 or CD8 being protective in small animal models. We defined the vaccine candidate recombinant fusion antigens, LEISH-F2 LEISH-F3+, when formulated a stable emulsion Toll-like receptor (TLR) 4 agonist induce CD4+ models, as well providing therapeutic...
Since chikungunya virus (CHIKV) was introduced into the Americas in 2013, its geographic distribution has rapidly expanded. Of 119 serum samples collected 2014 from febrile patients southern Mexico, 79% were positive for CHIKV or IgM against CHIKV. Sequencing results confirmed strains closely related to Caribbean isolates.
A total of 2,691 mosquitoes representing 17 species was collected from eight locations in southwest Cameroon and screened for pathogenic viruses. Ten isolates a novel reovirus (genus Dinovernavirus) were detected by culturing mosquito pools on Aedes albopictus (C6/36) cell cultures. virus that caused overt cytopathic effects isolated, but it did not infect vertebrate cells or produce detectable disease infant mice after intracerebral inoculation. The virus, tentatively designated Fako...
Most alphaviruses are mosquito borne and exhibit a broad host range, infecting many different vertebrates, including birds, rodents, equids, humans, nonhuman primates. Recently, host-restricted, mosquito-borne alphavirus, Eilat virus (EILV), was described with an inability to infect vertebrate cells based on defective attachment and/or entry, as well lack of genomic RNA replication. We investigated the utilization EILV recombinant technology vaccine platform against eastern (EEEV) Venezuelan...